Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.
Weight Gain : A Possible Side Effect of All Antiretrovirals / L. Taramasso, E. Ricci, B. Menzaghi, G. Orofino, S. Passerini, G. Madeddu, C.V. Martinelli, G.V. De Socio, N. Squillace, S. Rusconi, P. Bonfanti, A. Di Biagio. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 4:4(2017 Nov 03). [10.1093/ofid/ofx239]
Weight Gain : A Possible Side Effect of All Antiretrovirals
L. Taramasso;S. Passerini;S. Rusconi;
2017
Abstract
Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Taramasso et al. Weight gain CISAI, Open Forum ID 2017.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
113.2 kB
Formato
Adobe PDF
|
113.2 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
